Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE vs MARCAINE HYDROCHLORIDE W/ EPINEPHRINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Articaine is an amide local anesthetic that blocks sodium ion channels in nerve cell membranes, preventing depolarization and conduction of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the anesthetic effect by reducing local blood flow and systemic absorption.
Bupivacaine is an amide local anesthetic that blocks sodium channels on neuronal membranes, inhibiting the initiation and propagation of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the duration of action and reduces systemic absorption.
Local infiltration anesthesia for dental procedures,Nerve block anesthesia for dental procedures
Local and regional anesthesia for surgical procedures,Epidural anesthesia for labor and delivery,Peripheral nerve blocks,Dental procedures (off-label),Spinal anesthesia (off-label)
Adults: 1:100,000 epinephrine formulation (4% articaine) administered as a submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 500 mg (12.5 m L). 1:200,000 epinephrine formulation may be used; maximum dose same.
For local infiltration: 0.25-0.5% solution, up to 30 m L (75-175 mg bupivacaine) with epinephrine 1:200,000, not to exceed 3 mg/kg bupivacaine. For peripheral nerve block: 0.25-0.5% solution, up to 40 m L (100-200 mg). For epidural: 0.5% solution, 10-20 m L (50-100 mg). Maximum single dose: 225 mg with epinephrine.
Articaine: terminal half-life ~20 minutes (0.33 h) in plasma; clinical context: rapid elimination limits systemic toxicity. Epinephrine: short half-life ~2 minutes; clinical effect terminated by uptake and metabolism.
Terminal elimination half-life in adults is 2.7–3.4 hours (mean ~3.0 h). In neonates, it is prolonged (8–12 hours) due to immature hepatic function. Clinically, this supports continuous infusion intervals of 6–12 hours for epidural analgesia.
Articaine is primarily metabolized by plasma esterases (butyrylcholinesterase) to its inactive metabolite articainic acid. Epinephrine is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Bupivacaine is metabolized primarily in the liver via conjugation with glucuronic acid and via CYP3A4-mediated N-dealkylation to pipecolylxylidine. Epinephrine is metabolized by monoamine oxidase and catechol-O-methyltransferase.
Articaine is primarily metabolized by plasma esterases; its inactive metabolite articainic acid is excreted renally (approximately 90% as metabolites, <2% unchanged). Epinephrine is metabolized by COMT and MAO; metabolites and small amounts unchanged are excreted in urine (~90% renal).
Bupivacaine is metabolized in the liver primarily via CYP3A4 and CYP1A2. Approximately 6% is excreted unchanged in urine. The major metabolite, pipecolylxylidine (PPX), is excreted renally (80–90% of dose) with 2–5% as desbutylbupivacaine. Fecal elimination accounts for <5%. Biliary excretion of metabolites occurs but is minimal.
Articaine: ~60–80% bound to plasma proteins (primarily albumin). Epinephrine: ~50% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
~95% bound to alpha-1-acid glycoprotein (AAG) and, to a lesser extent, albumin. Binding is saturable; increased free fraction in acidosis or low AAG (e.g., neonates, pregnancy).
Articaine: Vd ~1.0 L/kg (healthy adults); large Vd indicates extensive tissue distribution. Epinephrine: Vd ~0.2 L/kg (predominantly in circulation and tissues).
Vd: 0.8–1.3 L/kg (mean ~0.9 L/kg). This indicates extensive tissue distribution, including highly perfused organs (brain, heart, liver). Higher Vd in neonates (~2.0 L/kg).
Not applicable for submucosal injection (100% bioavailable locally). Oral epinephrine has negligible bioavailability due to first-pass metabolism. For systemic effects, IV administration yields 100% bioavailability.
Bioavailability via epidural administration: ~100% (systemic absorption from the epidural space). Intrathecal: ~100% (but small dose, usually 2–3 mg). Subcutaneous: ~100% (absorption delayed by vasoconstriction). Oral: not available; high first-pass metabolism.
No dosage adjustment required for mild-to-moderate renal impairment; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of articaine metabolite; monitor for toxicity.
No dose adjustment required for mild to moderate renal impairment (GFR >= 30 m L/min). For severe renal impairment (GFR < 30 m L/min): use with caution, reduce dose by 25-50% and monitor for systemic toxicity due to potential accumulation of metabolites.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to reduced metabolism; consider reduced doses and monitor for prolonged effects.
Child-Pugh Class A: no dose adjustment needed. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or use with extreme caution, consider alternative local anesthetic.
Children ≥4 years: 4% articaine with 1:100,000 or 1:200,000 epinephrine; submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 7 mg/kg (absolute max 500 mg). For 1:100,000 formulation, maximum epinephrine dose 0.001 mg/kg (0.001 m L/kg) per injection.
For infiltration: 0.25-0.5% solution, 0.5-2 mg/kg bupivacaine with epinephrine, maximum single dose 2 mg/kg. For caudal epidural: 0.25-0.5% solution, 1-2 mg/kg. For peripheral nerve block: 0.25-0.5% solution, up to 2 mg/kg. Maximum total dose: 2 mg/kg for children <12 years.
No specific dose adjustment; consider reduced doses due to age-related decreased hepatic and renal function; monitor for prolonged anesthesia and cardiovascular effects; use lowest effective dose.
Reduce dose by 20-30% due to decreased clearance and increased sensitivity. Use lower concentrations (0.25-0.375%) and titrate slowly. Maximum dose: 2 mg/kg bupivacaine with epinephrine, not to exceed 150 mg.
Not available
There have been reports of cardiac arrest and death during use of bupivacaine for epidural anesthesia in obstetrical patients. Resuscitation has been difficult or impossible despite adequate preparation and proper management. Bupivacaine with epinephrine is not recommended for obstetrical paracervical block anesthesia for the same reason.
Risk of methemoglobinemia, especially in patients with glucose-6-phosphate dehydrogenase deficiency or hemoglobin abnormalities,Use with caution in patients with cardiovascular disease, hypertension, or hyperthyroidism due to epinephrine component,Avoid intravascular injection; may cause systemic toxicity or cardiovascular collapse,Caution in patients with hepatic or renal impairment,May cause allergic reactions or hypersensitivity; cross-sensitivity with other amide anesthetics is possible
Risk of cardiac toxicity, especially with inadvertent intravascular injection,Neurologic damage following spinal or epidural administration,Methemoglobinemia in susceptible patients,Avoid use in patients with severe hypotension or hypovolemia,Use caution in patients with hepatic impairment, as metabolism may be reduced,Increased risk of cardiotoxicity in elderly or debilitated patients,Avoid concurrent use with other local anesthetics or class I antiarrhythmics
Hypersensitivity to articaine, epinephrine, or any component of the formulation,Hypersensitivity to amide-type local anesthetics,Patients with severe uncontrolled hypertension or hyperthyroidism,Patients with known sulfite sensitivity (epinephrine contains sodium metabisulfite),Do not use in patients with paroxysmal tachycardia or other serious arrhythmias
Hypersensitivity to bupivacaine, epinephrine, or any component of the formulation,Severe hypertension or untreated thyrotoxicosis (due to epinephrine component),Concurrent use with MAO inhibitors or tricyclic antidepressants (due to epinephrine component),Use for paracervical block in obstetrics (black box warning),Severe hypotension or cardiogenic shock,Complete heart block or severe conduction disturbances
No known food-drug interactions. Avoid eating until numbness resolves to prevent oral trauma.
No specific food interactions. Caffeine-containing beverages may be consumed as usual. No dietary restrictions.
FDA Pregnancy Category C. No well-controlled studies in pregnant women. In animal studies, articaine and epinephrine have not shown teratogenic effects at clinically relevant doses. Risk to fetus cannot be ruled out. Use only if clearly needed. No specific trimester-associated risks identified; however, epinephrine may reduce uteroplacental blood flow, particularly if given with vasoconstrictors or during second/third trimester.
FDA Pregnancy Category C. First trimester: No adequate studies; animal studies show no teratogenicity at clinically relevant doses. Second trimester: No known teratogenic risk from bupivacaine; epinephrine may reduce uterine blood flow. Third trimester: Risk of fetal bradycardia, hypoxia, and acidosis with paracervical block; avoid in obstetric anesthesia due to potential for fetal acidosis and maternal seizures.
Articaine and epinephrine are excreted into breast milk in low amounts. M/P ratio not available. The American Academy of Pediatrics considers articaine compatible with breastfeeding. However, theoretical risk of cardiovascular effects in infant exists. Use with caution, and advise mother to pump and discard milk for 4-6 hours after administration to minimize exposure.
Bupivacaine is excreted into breast milk in small amounts (M/P ratio approximately 0.3). No adverse effects reported in nursing infants. Epinephrine is not orally bioavailable. Use with caution; infant exposure is minimal.
No specific dose adjustment required based on pharmacokinetic changes in pregnancy. However, due to increased plasma volume and cardiac output, higher doses may be needed to achieve adequate anesthesia? Typically, lowest effective dose is recommended. Avoid excessive epinephrine (max 0.1 mg per appointment) to minimize risk of uteroplacental vasoconstriction.
No routine dose adjustment required; however, pregnancy may increase sensitivity to local anesthetics due to hormonal changes. Use lowest effective dose. Increased vascularity may require higher doses for epidural anesthesia; reduce dose for paracervical blocks to avoid fetal exposure.
Aspirate before injection to prevent intravascular administration. Maximum dose: 7 mg/kg articaine (0.175 m L/kg of 4% solution with 1:100,000 epinephrine). Avoid in patients with hepatic porphyria. Use with caution in patients with sulfite allergy (epinephrine component contains sodium metabisulfite).
Limit total bupivacaine dose to 2 mg/kg with epinephrine; avoid in paracervical block (obstetric) due to fetal toxicity. Do not use for IV regional anesthesia (Bier block) as cardiac toxicity risk is high. Epinephrine-containing formulation prolongs block duration and reduces systemic absorption but vasoconstriction may delay wound healing in certain tissues.
You may experience temporary numbness of the tongue, lips, or face; avoid eating or drinking until sensation returns to prevent biting yourself.,Do not drive or operate machinery for at least 2 hours after administration, or until numbness resolves.,Contact your dentist or doctor immediately if you experience chest pain, difficulty breathing, rapid heartbeat, or severe headache after injection.,Inform your healthcare provider if you have heart disease, high blood pressure, thyroid problems, or are taking MAO inhibitors or tricyclic antidepressants.
This medicine is a local anesthetic used to numb a specific area of your body, often to prevent pain during surgery or dental procedures.,You may feel a burning sensation when the injection is first given, but numbness should occur quickly.,Avoid touching or scratching the numb area until sensation returns to prevent injury.,Report any signs of allergic reaction (rash, itching, swelling) or severe headache, stiff neck, or mental status changes after injection.,Do not drive or operate machinery until numbness wears off, as your coordination or reflexes may be impaired.
"The concurrent use of acepromazine, a phenothiazine neuroleptic with significant α1-adrenergic receptor antagonism, and articaine, an amide local anesthetic, may result in enhanced hypotensive and arrhythmogenic effects. Acepromazine-induced vasodilation and decreased peripheral resistance, combined with articaine's potential for myocardial depression and conduction disturbances, particularly in cases of inadvertent intravascular injection, can precipitate severe hypotension and ventricular arrhythmias. Additionally, phenothiazines can potentiate the central nervous system depressant effects of local anesthetics, increasing the risk of sedation and respiratory depression."
"Coadministration of articaine, an amide local anesthetic that inhibits voltage-gated sodium channels, and levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may increase the risk of adverse cardiovascular effects, particularly hypertension and arrhythmias. The SNRI's enhancement of norepinephrine activity can potentiate sympathomimetic responses, while articaine's sodium channel blockade may exacerbate conduction abnormalities. This combination requires caution due to potential for additive cardiotoxicity."
"Dextropropoxyphene, a centrally acting opioid analgesic, may cause additive central nervous system depression and respiratory depression when combined with articaine, a local anesthetic. This interaction can lead to profound sedation, respiratory compromise, and increased risk of bradycardia and hypotension. Co-administration requires careful patient monitoring to prevent serious adverse outcomes, especially in elderly or debilitated patients."
"Epinephrine, a catecholamine with potent beta-2 adrenergic agonist activity, can antagonize the hypoglycemic effect of tolbutamide, a sulfonylurea insulin secretagogue. By stimulating hepatic gluconeogenesis and glycogenolysis, epinephrine increases blood glucose levels, potentially reducing tolbutamide's efficacy in lowering glucose. This interaction may lead to diminished glycemic control, particularly in diabetic patients under stress or during epinephrine administration for anaphylaxis or hypotension."
"Epinephrine, a non-selective alpha and beta adrenergic agonist, can antagonize the antihypertensive effects of clomipramine, a tricyclic antidepressant (TCA) that inhibits norepinephrine reuptake. Concomitant use may lead to enhanced sympathetic activity, potentially causing severe hypertension, tachycardia, and increased risk of arrhythmias. This interaction is particularly concerning during local anesthetic procedures involving epinephrine or systemic administration in patients on clomipramine."
"Epinephrine, a sympathomimetic amine with potent beta-2 adrenergic agonist activity, can directly antagonize the insulin-sensitizing effects of pioglitazone by stimulating glycogenolysis and gluconeogenesis, leading to increased hepatic glucose output and reduced peripheral glucose uptake. This functional antagonism may result in a significant elevation of blood glucose levels, thereby diminishing the therapeutic efficacy of pioglitazone in managing type 2 diabetes. In diabetic patients, the interaction may precipitate acute hyperglycemia, requiring dosage adjustments or alternative therapeutic strategies."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE vs MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, answered by our medical review team.
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is a Alpha/Beta Agonist that works by Articaine is an amide local anesthetic that blocks sodium ion channels in nerve cell membranes, preventing depolarization and conduction of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the anesthetic effect by reducing local blood flow and systemic absorption.. MARCAINE HYDROCHLORIDE W/ EPINEPHRINE is a Alpha/Beta Agonist that works by Bupivacaine is an amide local anesthetic that blocks sodium channels on neuronal membranes, inhibiting the initiation and propagation of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the duration of action and reduces systemic absorption.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE and MARCAINE HYDROCHLORIDE W/ EPINEPHRINE depend on the specific clinical indication. These are both Alpha/Beta Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is: Adults: 1:100,000 epinephrine formulation (4% articaine) administered as a submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 m L/kg) per appointment, not to exceed 500 mg (12.5 m L). 1:200,000 epinephrine formulation may be used; maximum dose same.. The standard adult dose of MARCAINE HYDROCHLORIDE W/ EPINEPHRINE is: For local infiltration: 0.25-0.5% solution, up to 30 m L (75-175 mg bupivacaine) with epinephrine 1:200,000, not to exceed 3 mg/kg bupivacaine. For peripheral nerve block: 0.25-0.5% solution, up to 40 m L (100-200 mg). For epidural: 0.5% solution, 10-20 m L (50-100 mg). Maximum single dose: 225 mg with epinephrine.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE and MARCAINE HYDROCHLORIDE W/ EPINEPHRINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE is classified as Category A/B. FDA Pregnancy Category C. No well-controlled studies in pregnant women. In animal studies, articaine and epinephrine have not shown teratogenic effects at clinically relevant doses. MARCAINE HYDROCHLORIDE W/ EPINEPHRINE is classified as Category A/B. FDA Pregnancy Category C. First trimester: No adequate studies; animal studies show no teratogenicity at clinically relevant doses. Second trimester: No known teratogenic risk from. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.